Skip to content

Advertisement

Cardiovascular Diabetology

Open Access

Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

  • Toshiyuki Hayashi1Email author,
  • Tomoyasu Fukui1,
  • Noriko Nakanishi1,
  • Saki Yamamoto1,
  • Masako Tomoyasu1,
  • Anna Osamura1,
  • Makoto Ohara1,
  • Takeshi Yamamoto1,
  • Yasuki Ito2 and
  • Tsutomu Hirano1Email author
Cardiovascular Diabetology201716:149

https://doi.org/10.1186/s12933-017-0608-5

Received: 3 October 2017

Accepted: 3 October 2017

Published: 13 November 2017

The original article was published in Cardiovascular Diabetology 2017 16:8

Correction to: Cardiovasc Diabetol (2017) 16:8 DOI 10.1186/s12933-016-0491-5

Following publication of the original article [1], the authors identified a number of errors. In Result (P.3), Table 1 (P.4), Table 5 (P.9) and Supplementary Table 1, the correct unit for adiponectin was μg/mL. In Table 1 (P.4), the correct value for the post treatment body weight in dapagliflozin was 76.2±14.8. In Table 6 (P.10), the correct value for the pre treatment sd LDL/LDL-C in decreased LDL-C group was 0.38±0.10.

Notes

Declarations

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
(2)
Reagent R&D Department, Denka Seiken Co., Ltd., Tokyo, Japan

Reference

  1. Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16:8. doi:10.1186/s12933-016-0491-5.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement